COMMUNIQUÉS West-GlobeNewswire

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
28/01/2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
28/01/2026
MONTREAL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
HealthEdge® and Suki Introduce Ambient Clinical Intelligence for Care Management
28/01/2026
Integration of Suki with HealthEdge GuidingCare® Delivers AI-Powered Automation That Reduces Administrative Burden for Care Managers and Elevates Care Quality BOSTON and REDWOOD CITY, Calif., Jan. 28, 2026 (GLOBE [...]
Wandercraft Appoints Permobil CEO Chuck Witkowski to Board of Directors, Signaling a New Phase of Growth and Global Commercialization
28/01/2026
PARIS and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Wandercraft, a pioneer in the development of self-balancing robotics, today announced the appointment of Chuck Witkowski, CEO of Permobil, to its Board of Directors [...]
Autonomix Medical to Present Final Analysis on Pain Mitigation in Pancreatic Cancer at SIO 2026 Annual Scientific Meeting
28/01/2026
THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
28/01/2026
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion Woodland, CA, Jan. 28, 2026 (GLOBE [...]
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
28/01/2026
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” [...]
DXS International plc (AQSE: DXSP): Half-year Financial Report
28/01/2026
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results [...]
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
28/01/2026
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional [...]
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
28/01/2026
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28/01/2026
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues [...]
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
28/01/2026
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People [...]
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
28/01/2026
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris Hagedorn to its Board of Directors MINNEAPOLIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vireo [...]
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
28/01/2026
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and [...]
OKYO Pharma Announces Successful Type C Meeting with the FDA
28/01/2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage [...]
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
28/01/2026
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, [...]
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28/01/2026
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the [...]

Pages